<DOC>
	<DOC>NCT01660945</DOC>
	<brief_summary>The investigator hypothesize that vytorin may improve vascular and insulin resistance in hypercholesterolemic patients</brief_summary>
	<brief_title>Vascular and Metabolic Effects of Vytorin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<criteria>hypercholesterolemia overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c &gt; 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>statins, insulin resistance</keyword>
</DOC>